This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
home:food:aim_health:aging [02.01.2019] – [Long term treatment] sallieq | home:food:aim_health:aging [02.09.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 7: | Line 7: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
- | |||
- | | ||
In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
Line 15: | Line 13: | ||
The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
+ | |||
+ | | ||
The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> |